Last reviewed · How we verify
NCT06685237: CPH-HFpEF
Copenhagen Heart Failure With Preserved Ejection Fraction
trial in Heart Failure With Preserved Ejection Fraction (HFPEF) in 5,000 participants. Currently enrolling.
28 November 2025
Quick facts
| Lead sponsor | Tor Biering-Sørensen |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 5,000 |
| Start date | 28 February 2025 |
| Primary completion | 28 November 2025 |
| Estimated completion | 28 March 2026 |
| Sites | 1 location across Denmark |
Conditions studied
- Heart Failure With Preserved Ejection Fraction (HFPEF) — all drugs for Heart Failure With Preserved Ejection Fraction (HFPEF) →
Sponsor
Tor Biering-Sørensen — full company profile →
Who can join
Adults 50 to 89, any sex, with Heart Failure With Preserved Ejection Fraction (HFPEF). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Heart failure with preserved ejection fraction (HFpEF) has grown to become the dominant form of heart failure (HF) worldwide, in tandem with ageing of the general population and the increasing prevalence of obesity, diabetes mellitus and hypertension. In 2020, \> 70% of patients with heart failure had preserved ejection fraction. The incidence and prevalence of HFpEF has been growing by 10% every 10 years relative to HF with reduced ejection fraction (HFrEF). In 2017, the prevalence of HFpEF varied from 1% to 14% based on available data from Europe and USA. HFpEF is associated with high morbidity and mortality, and patients with HFpEF have similarly high hospitalization rates as patients with HFrEF. Hence, HFpEF poses a substantial global health challenge. Despite its prevalence, HFpEF remains undiagnosed and underrecognized, necessitating a comprehensive approach to both identification and management. Ensuring successful treatment necessitates early identification of HFpEF. Consequently, a targeted screening strategy has been devised for the identification of HFpEF patients. Given the higher prevalence of heart failure (HF) in the elderly population, testing the screening strategy is imperative to customize it to the specific needs of vulnerable patients who may be more inclined to decline participation in the screening program.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06685237
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Failure With Preserved Ejection Fraction (HFPEF)
Currently open trials in the same condition.
- NCT07185100 — Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using · recruiting
- NCT06905405 — The Use of Advanced Imaging in HFpEF · recruiting
- NCT06909682 — AI-Based Monitoring System for Chronic Heart Failure With Advanced Wearable and Mini-Invasive Devices · recruiting
- NCT07053475 — IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches · Phase 4 · recruiting
- NCT06862908 — A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity · Phase 2 · recruiting
Other Tor Biering-Sørensen trials
Trials by the same sponsor.
- NCT06952140 — Hemodynamic Effects of Ketone Esters in Patients With Sepsis Induced Cardiomyopathy · NA · not yet recruiting
- NCT06694727 — A Danish Pragmatic Randomized Trial of Nutritional Supplements in Heart Failure · Phase 3 · recruiting
- NCT06506812 — Pooled Analysis of Methodologically Harmonized Pragmatic Randomized Trials of High-Dose vs. Standard-Dose Influenza Vacc · Phase 4 · completed
- NCT06856772 — Randomized Comparison of Morning Versus Bedtime Administration of Statins: A Cardiovascular Circadian Chronotherapy (C3) · Phase 4 · not yet recruiting
- NCT06600490 — Nationwide Utilization of Danish Government Electronic Letter System for Confirming the Effectiveness of Behavioral Nudg · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06685237 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tor Biering-Sørensen
- Last refreshed: 5 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06685237.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing